Investment Rating - The report maintains a "Strong Buy" rating for the company with a target price of HKD 12.45 [2][9] Core Insights - The company reported a revenue of HKD 14.256 billion for 2025, representing a year-on-year increase of 20.8%. Adjusted net profit was HKD 1.530 billion, up 1.3% year-on-year, with an adjusted net profit margin of 10.7%, down 2.1 percentage points from the previous year [2][5] - The HNB (Heat-not-Burn) business is experiencing significant growth, with revenue surpassing HKD 12.5 billion, compared to HKD 2.2 billion in 2024. The new products have received positive consumer feedback, contributing to market share gains [9] - The vaporization business benefits from stricter industry regulations, enhancing the company's competitive advantage as a leading electronic vaporization device manufacturer [9] Financial Summary - For 2025, the company achieved total revenue of HKD 14.256 billion, with a projected growth rate of 20.8% for the year. The adjusted net profit is expected to be HKD 1.064 billion, with a decline of 18.4% year-on-year [5][10] - The company anticipates continued revenue growth, with projections of HKD 16.700 billion in 2026, HKD 19.977 billion in 2027, and HKD 23.011 billion in 2028 [5][10] - The adjusted net profit is forecasted to recover to HKD 1.265 billion in 2026, HKD 1.850 billion in 2027, and HKD 2.372 billion in 2028, with corresponding P/E ratios of 39, 27, and 21 respectively [5][10]

Investment Rating - The report maintains a "Strong Buy" rating for Smoore International (06969.HK) with a target price of HKD 12.45 [2][9] Core Insights - In 2025, Smoore International achieved revenue of HKD 14.256 billion, representing a year-on-year increase of 20.8%. The adjusted net profit was HKD 1.530 billion, up 1.3% year-on-year, with an adjusted net profit margin of 10.7%, down 2.1 percentage points from the previous year [2][5] - The HNB (Heat-not-Burn) business is expanding, contributing significantly to revenue growth, with HNB revenue surpassing HKD 1.25 billion in 2025, compared to HKD 220 million in 2024. The company is expected to continue supporting strategic customers in promoting HNB products globally [9][10] - The vaping business benefits from stricter industry regulations, enhancing the market position of compliant companies like Smoore. The ODM (Original Design Manufacturer) business generated revenue of HKD 11.34 billion, up 21.7% year-on-year, with notable growth in Europe and the U.S. markets [9][10] Financial Summary - Total revenue for 2025 is projected at HKD 14.256 billion, with expected growth rates of 17.1%, 19.6%, and 15.2% for 2026, 2027, and 2028 respectively [5][10] - The adjusted net profit for 2025 is estimated at HKD 1.064 billion, with a projected growth rate of -18.4% for 2026, followed by 18.9% and 46.2% for 2027 and 2028 respectively [5][10] - The company’s gross margin for 2025 is reported at 34.1%, down 3.3 percentage points year-on-year, primarily due to a higher proportion of lower-margin products [9][10]

Investment Rating - The investment rating for the company is "Outperform the Market" [7] Core Views - The company's revenue for the first half of 2025 reached 6.013 billion HKD, representing a year-on-year increase of 18.3%, while adjusted profit slightly decreased by 2.1% to 737 million HKD [1] - The company is benefiting from the global trend towards regulatory compliance, with its vaping business recovering as expected [1] - The company plans to distribute an interim dividend of 0.20 HKD per share [1] Revenue and Profit Analysis - The company's To B business revenue increased by 19.5% year-on-year to 4.74 billion HKD, with European revenue growing by 38.0% to 2.73 billion HKD [2] - In the U.S., revenue was 1.5% higher at 1.89 billion HKD, while domestic revenue decreased by 6.1% to 120 million HKD [2] - The self-owned brand business revenue grew by 14.1% year-on-year to 1.27 billion HKD, with European revenue increasing by 15.1% [3] Long-term Growth Potential - The successful commercialization of HNB products and steady progress in vaping medical applications are expected to drive long-term growth [3] - The company launched high-end HNB products in Japan, with plans for nationwide expansion and entry into more key markets in the second half of 2025 [3] Financial Forecasts - The profit forecast for 2025-2027 has been adjusted, with expected net profits of 1.239 billion HKD, 1.822 billion HKD, and 2.565 billion HKD respectively, reflecting year-on-year changes of -4.9%, +47.0%, and +40.8% [4] - The diluted EPS is projected to be 0.20, 0.29, and 0.41 HKD for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 98, 67, and 48 [4]

Core Viewpoint - The company's 1H25 performance aligns with expectations, showing revenue growth but a decline in net profit, indicating a mixed financial outlook amid evolving market conditions [1][2]. Financial Performance - Revenue for 1H25 reached 6.01 billion, an 18.3% year-on-year increase, while net profit attributable to shareholders was 500 million, a 30.8% decline. Adjusted net profit after stock incentive expenses was 740 million, down 2.1% [1]. - The company declared an interim dividend of 0.2 HKD per share, with a payout ratio of 225.1%, significantly higher than the 38.7% in 1H24, indicating increased shareholder returns [1]. Market Trends - The ToB revenue grew by 19.5% to 4.739 billion, driven by strong performance in Europe and potential improvements in the U.S. market due to stricter regulations [1]. - In Europe, revenue surged by 38% to 2.73 billion, benefiting from regulatory changes that favored compliant companies [1]. - U.S. revenue increased by 1.5% to 1.89 billion, with expectations of continued improvement as enforcement tightens [1]. - Domestic revenue, however, saw a decline of 6.1% to 120 million [1]. Product Development - The ToC revenue rose by 14.1% to 1.274 billion, with significant growth in the APV segment, particularly in Europe, where new product launches are driving user conversion [2]. - The APV revenue in Europe and the U.S. was 1.07 billion and 170 million, respectively, with declines of 15.1% and 6.7% [2]. - The nebulization beauty segment experienced a remarkable growth of 2595% to 30.618 million, with over 10,000 C-end users and more than 100 B-end partnerships established [2]. Profitability and Costs - The overall gross margin remained stable, decreasing slightly by 0.5 percentage points to 37.3%. However, the net profit margin fell by 5.9 percentage points to 8.3%, and adjusted for stock incentive expenses, it decreased by 1.2 percentage points to 12.3% [2]. - Sales expense ratio increased by 0.8 percentage points to 8.2% due to heightened investment in self-owned brands, while R&D expense ratio decreased by 2.9 percentage points to 12% [2]. - Management expenses rose significantly by 15.5 percentage points to 22.2%, primarily due to increased stock incentive costs [2]. Growth Outlook - The HNB segment is expected to accelerate globally, with Glo Hilo's market share in Japan increasing by 1.5% during its sales period, indicating strong growth potential [3]. - The regulatory environment for vaping products in Europe and the U.S. is expected to lead to a more standardized industry, allowing the company to recover market share and continue growing [3]. - The company is also focusing on developing nebulization medical products and expanding its nebulization beauty segment domestically, which opens up additional growth opportunities [3]. Profit Forecast and Valuation - The company maintains its profit forecast and industry outperform rating, with a target price reflecting a 4% upside from the current stock price [3].

Investment Rating - The report does not provide a specific investment rating for the company [1] Core Insights - The company reported a revenue of 6.013 billion yuan for H1 2025, representing a year-on-year increase of 18.3%, while net profit decreased by 28.0% to 492 million yuan [1] - The company's proprietary brand business revenue reached 1.274 billion yuan in H1 2025, up 14.1% year-on-year, with significant growth in the European market [2] - The company is experiencing a recovery in the European vaping market, with a strong response to new compliant products, while the U.S. market is expected to stabilize due to tightening regulations [3] - The company is optimizing R&D expenses and maintaining stable operational capabilities, with a gross margin of 37.3% and an adjusted net profit margin of 12.3% in H1 2025 [4] Financial Performance Summary - For 2025-2027, the company is projected to achieve net profits of 1.228 billion yuan, 2.013 billion yuan, and 3.058 billion yuan, with corresponding P/E ratios of 103.4X, 63.1X, and 41.6X [4] - The total revenue is expected to grow from 11.799 billion yuan in 2024 to 19.291 billion yuan in 2027, with a year-on-year growth rate of 18% in 2027 [6] - The company's cash flow from operating activities is projected to improve significantly, reaching 2.680 billion yuan by 2027 [9]